The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
Arco Lab now holds a 50% stake in Neviton
Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens
Star Health's convenient claims process, valued added offerings like free telemedicine consultations with expert doctors
Sirius JV will be owned 51% by Sirius and 49% by Adani
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
Furthering cell therapy ambition across oncology and autoimmune diseases
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
Clariant Healthcare highlighted Vitipure Meglumine LEX and VitiPure Superior at the recently concluded CPhI India
Five batches across four programs of Biocon Academy participated in the graduation ceremony
Subscribe To Our Newsletter & Stay Updated
